<qa>  What is the name of the drug that is used to treat the participant?14. The participant has been treated with any of the following drugs within the 8 weeks prior to VISIT 2: oral contraceptive or sex hormone preparations norethindrone, norethisterone, medroxyprogesterone, estrogen, or other progestins, and within the 16 weeks prior to VISIT 2: gonadotropin-releasing hormone GnRH analogues, dienogest, danazol, or aromatase inhibitors for 1- and 3-month sustained-release preparations, within the 20 and 28 weeks prior to VISIT 2, respectively. 